Meitheal is Ranked #4 on Crain’s 2023 Fast 50 in Chicago

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, is proud to be ranked #4 on Crain’s Chicago Business 2023 Fast 50.

“Meitheal was among a variety of companies showcased that have demonstrated significant revenue growth in a five-year period,” said CEO Tom Shea. “This is a huge accomplishment for Meitheal and we are very proud of the entire team for this award.”

Crain’s Chicago Business is the nation's pre-eminent regional business newspaper that delivers breaking news, cutting-edge analysis, thoughtful opinion and informative events to Chicago's corporate, civic and cultural leaders through a weekly print edition as well as through a suite of curated newsletters centered on the publication's website, ChicagoBusiness.com. The Fast 50 provides a full ranking and exclusive profiles on Chicago’s fastest-growing companies in 2023.

With a 5-year revenue growth of over 36,000%, Meitheal’s steady climb can be attributed in part to its parent company, China-based manufacturer Nanjing King Friend (NKF), which allows Meitheal to reduce costs as much as possible in its mission to provide quality, affordable injectables to patients, and to get new products approved and to market quickly.

WE’RE HIRING!

Looking to grow your career at a company that puts its people first? Visit our careers page at: www.meithealpharma.com.

ABOUT MEITHEAL PHARMACEUTICALS

Founded in 2017 and based in Chicago, Meitheal Pharmaceuticals is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and biosimilar products. Meitheal currently markets over 50 US Food and Drug Administration (FDA)-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of the end of June 2023, Meitheal, directly or through its partners, has over 20 products in the research and development phase, 21 products planned for launch in 2023, and an additional 20 products under review by the FDA. Meitheal’s mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers’ needs. Ranked among the top 100 Crain’s Best Places to Work in Chicago, Meitheal emulates the traditional Irish guiding principle we are named for — Meitheal (Mee·hall): working together toward a common goal, for the greater good.

Learn more about who we are and what we do at www.meithealpharma.com.